The controversy stems from a July 14, 2026, announcement regarding the FDA-approved drug gedatolisib. While Celcuity confirmed the regulatory green light, the company revealed that the commercial launch would not occur until late in the third quarter of 2026. This timeline significantly lagged behind projections held by market analysts, prompting an immediate sell-off that wiped out a substantial portion of the company’s market value.
Attorneys Brian Schall and David Schwartz are now examining whether Celcuity’s previous public disclosures contained material omissions or false statements that obscured the true status of the product rollout. Investors who suffered financial losses are being invited to contact the Los Angeles-based firm to discuss potential participation in a securities litigation claim.
Comments (0)
No comments yet. Be the first!